This entry covers evaluation under DC 6731. A clinician establishes the diagnosis separately.
How is it connected to service?
The applicable direct, secondary, aggravation or presumptive route determines the service-connection evidence. Use the evidence guide to distinguish these routes.
Explore service-connection evidence →What do the rating levels describe?
A diagnosis does not automatically establish a percentage. These are the source requirements for evaluating severity; related notes and exceptions still apply.
Find DC 6731 in the rating schedule
The highlighted row marks this code. Nearby rows provide context and can describe other conditions. Use the full schedule for applicable headings, footnotes and exceptions.
| Rating | |
|---|---|
| (d) With advancement of lesions on successive examinations or while under treatment. | |
| (e) Without retrogression of lesions or other evidence of material improvement at the end of six months hospitalization or without change of diagnosis from “active” at the end of 12 months hospitalization. Material improvement means lessening or absence of clinical symptoms, and X-ray findings of a stationary or retrogressive lesion. | |
| 6731 Tuberculosis, pulmonary, chronic, inactive: | |
| Depending on the specific findings, rate residuals as interstitial lung disease, restrictive lung disease, or, when obstructive lung disease is the major residual, as chronic bronchitis (DC 6600). Rate thoracoplasty as removal of ribs under DC 5297. | |
| Note: A mandatory examination will be requested immediately following notification that active tuberculosis evaluated under DC 6730 has become inactive. Any change in evaluation will be carried out under the provisions of § 3.105(e). | |
| 6732 Pleurisy, tuberculous, active or inactive: | |
| Rate under §§ 4.88c or 4.89, whichever is appropriate. | |
| NONTUBERCULOUS DISEASES | |
| 6817 Pulmonary Vascular Disease: | |
How VA handles coexisting respiratory conditions
When more than one listed respiratory condition is present, check the predominant-disability rule before combining ratings. The special pulmonary-function-test provisions apply only to the codes listed in subsection (d).
Read 38 CFR §4.96 ↗Related notes and evaluation rules
Note: A mandatory examination will be requested immediately following notification that active tuberculosis evaluated under DC 6730 has become inactive. Any change in evaluation will be carried out under the provisions of § 3.105(e).
Depending on the specific findings, rate residuals as interstitial lung disease, restrictive lung disease, or, when obstructive lung disease is the major residual, as chronic bronchitis (DC 6600). Rate thoracoplasty as removal of ribs under DC 5297. |
Note: A mandatory examination will be requested immediately following notification that active tuberculosis evaluated under DC 6730 has become inactive. Any change in evaluation will be carried out under the provisions of § 3.105(e). |
Which evidence addresses the questions?
- The documented diagnosis and applicable diagnostic code.
- Clinical findings and functional effects addressing the applicable source criteria.
- Timing, treatment and connection-to-service evidence for the applicable claim route.
Find evidence in the Tuberculosis questionnaire
Use these section names and page numbers to locate the examiner’s findings. Some sections apply only to particular diagnoses within this family.
- diagnosis · p. 1, 2
- medical history · p. 2
- pulmonary tb · p. 2, 3
- non-pulmonary tb · p. 3, 4
- other pertinent physical findings, complications, conditions, signs and/or symptoms · p. 4
- diagnostic testing · p. 5, 6
- functional impact · p. 6
- remarks · p. 7
Shared library and examination references
How an independent medical review works →Sources and scope
Clinical and evidence sources
Guide source check: 2026-11-06. Rating-library snapshot: June 30, 2026. Source coverage is distinct from clinical review. This page does not diagnose, adjudicate a claim, or collect medical records.
Shared reference edition 1.2.4 · source check 2026-11-06. Coverage is stated for each framework and is distinct from clinical review. Rating-source snapshot: 2026-06-30.